newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026

  • Ascentage Pharma announced multiple clinical & preclinical studies selected for the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans from December 12-15, 2026.
  • Four proprietary drug candidates were featured: olverembatinib (HQP1351), lisaftoclax (APG-2575), APG-5918, & APG-3288.
  • APG-5918 received an oral presentation slot for its first disclosure of clinical data in relapsed/refractory T-cell lymphoma (R/R TCL).
  • APG-5918 Phase 1 data showed a 44.7% objective response rate in R/R TCL patients, with a 65.0% rate in the 600 mg daily dose cohort.
  • Olverembatinib combined with blinatumomab demonstrated an 80% major molecular response rate in patients with relapsed/refractory Ph+ BCP ALL & CML-LBP.
  • A chemotherapy-free regimen of olverembatinib & lisaftoclax achieved a 90% overall response rate with 100% complete remission in pediatric relapsed/refractory Ph+ ALL.
  • Olverembatinib-based combination therapy achieved 100% complete remission rates in pediatric patients with newly diagnosed Ph+ ALL.
  • A triplet regimen of olverembatinib, lisaftoclax, & azacitidine showed a 30% overall response rate in venetoclax-relapsed/refractory acute myeloid leukemia patients.
  • Preclinical data indicated APG-5918 exhibits synergistic antitumor activity with lisaftoclax in diffuse large B-cell lymphoma models.
  • APG-3288, a BTK protein degrader, was listed as a trial in progress for relapsed/refractory B-cell malignancies.
  • The company highlighted its ongoing global Phase III trials for olverembatinib (POLARIS-1, -2, -3) & lisaftoclax (GLORA series).
  • Dr. Yifan Zhai, Chief Medical Officer, emphasized the global recognition of the company's pipeline & commitment to advancing hematologic malignancy treatments.